Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 3/2006

01-06-2006 | ORIGINAL ARTICLE

Historical control study of paclitaxel–carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer

Authors: Reiko Numazaki, Etsuko Miyagi, Ryo Onose, Tsuneo Nakazawa, Ken Sugiura, Kunio Asukai, Hiroki Nakayama, Atsushi Miyamatsu, Naoyuki Okamoto, Fumiki Hirahara

Published in: International Journal of Clinical Oncology | Issue 3/2006

Login to get access
Metadata
Title
Historical control study of paclitaxel–carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer
Authors
Reiko Numazaki
Etsuko Miyagi
Ryo Onose
Tsuneo Nakazawa
Ken Sugiura
Kunio Asukai
Hiroki Nakayama
Atsushi Miyamatsu
Naoyuki Okamoto
Fumiki Hirahara
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 3/2006
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-005-0555-0

Other articles of this Issue 3/2006

International Journal of Clinical Oncology 3/2006 Go to the issue

REVIEW ARTICLE

Biological and clinical implications of EGFR mutations in lung cancer

ORIGINAL ARTICLE

Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer

REVIEW ARTICLE

Molecular targeting therapy for renal cell carcinoma

REVIEW ARTICLE

Gastrointestinal stromal tumor (GIST) and imatinib

EDITORIAL

Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?

REVIEW ARTICLE

Methodological aspects of current problems in target-based anticancer drug development
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits